Protagonist Therapeutics, Inc.

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) resulting from allegations that Protagonist Therapeutics may have issued materially misleading business information to the investing public.

If you purchased Protagonist Therapeutics securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased Protagonist Therapeutics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On April 13, 2022, after market hours, Protagonist Therapeutics disclosed in a filing with the U.S. Securities and Exchange Commission that “[t]he Company has received a letter from United States Food and Drug Administration (the “FDA”) indicating the FDA’s intent to rescind Breakthrough Therapy Designation for the Company’s rusfertide product candidate in polycythemia vera,” citing “observed malignancies[.]”

On this news, Protagonist’s stock price fell $5.57 per share, or 21%, to close at $19.95 per share on April 14, 2022.

公司名称: Protagonist Therapeutics, Inc.
股票代号: PTGX
集体诉讼期: N/A
法院: N/A


自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。


机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。